24/7 Market News Snapshot 27 May, 2025 – Mangoceuticals, Inc. Common Stock (NASDAQ:MGRX)

May 27, 2025

DENVER, Colo., 27 May, 2025 (www.247marketnews.com) – (NASDAQ:MGRX) are discussed in this article.
Mangoceuticals, Inc. (MGRX) experienced a notable increase in its stock price, opening at $1.72 and currently trading at $1.886, marking an impressive gain of 11.6%. The previous closing price was $1.690, indicating robust buyer interest and increased investor engagement, as evidenced by a trading volume of 523.27K. This upward momentum suggests that MGRX has successfully breached its previous resistance level, which could lead to further gains. Analysts note that sustaining a price above $1.85 may foster a bullish market sentiment; however, any retreat below $1.72 could signal profit-taking and a potential weakening of bullish dynamics.

In addition to its stock performance, Mangoceuticals is excited to report significant findings from a series of recent field studies conducted on its antiviral compound, MGX-0024. These studies, managed by Solice International, focused on combating respiratory diseases in poultry, such as Newcastle Disease and Chronic Respiratory Disease (CRD). Remarkably, the results revealed a 100% survival rate in treated chickens, indicating a breakthrough in poultry health and avian flu mitigation.

In one pivotal study involving 8,000 chickens, those treated with MGX-0024 through their drinking water exhibited drastically lower mortality rates, with only 50 deaths occurring daily compared to 200 deaths on a nearby untreated farm. A subsequent study supported these findings, where 10,000 chicks that received MGX-0024 from just 7 days old recorded no deaths from respiratory disease, in contrast to an expected mortality rate of 50%.

Formulated from a blend of natural polyphenols and zinc, MGX-0024 is categorized as Generally Regarded as Safe (GRAS) and is in the process of being evaluated for avian flu prevention. Jacob Cohen, Co-Founder and CEO, emphasized the potential of MGX-0024 as a groundbreaking, non-toxic alternative to traditional vaccination and antibiotic methods.

Mangoceuticals is rapidly advancing towards the commercialization of MGX-0024 and aims to collaborate with large-scale farms globally, focusing on regulatory approvals and pilot deployments. Future trials are on the horizon to further substantiate the efficacy of MGX-0024, particularly in regions affected by H5N1, underscoring the company’s commitment to antibiotic-free poultry and enhanced biosecurity standards in agriculture.

Related news for (MGRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.